Abstract
Treatment with sclerostin antibody (romosozumab) increases bone formation while reducing bone resorption, leading to increases in bone volume and bone mineral density. Sclerostin antibody treatment may also provide beneficial changes in trabecular microarchitecture and strength that are not reflected in bone volume and density. Here we use three-dimensional dynamic histomorphometry to determine longitudinal changes in vertebral trabecular microarchitecture in adolescent male cynomolgus monkeys (4–5 years old) treated with sclerostin antibody. Animals were treated bi-weekly with either sclerostin antibody (30 mg/kg, sc, n = 6) or vehicle (n = 6) for 10 weeks. Animals were administered fluorochrome bone formation labels on days 14 and 24 (tetracycline) and on days 56 and 66 (calcein), followed by necropsy on day 70. Cylindrical specimens of cancellous bone from the 5th lumbar vertebrae were used to generate high-resolution, three-dimensional images of bone and fluorescent labels of bone formation (0.7 × 0.7 × 5.0 µm/voxel). The three-dimensional images of the bone formation labels were used to determine the bone volume formed between days 14 and 66 and the resulting alterations in trabecular microarchitecture within each bone. Treatment with sclerostin antibody resulted in a conversion of rod-like trabeculae into plate-like trabeculae at a higher rate than in vehicle-treated animals (p = 0.01). Plate bone volume fraction was greater in the sclerostin antibody group relative to vehicle (mean 43 vs. 30%, p < 0.05). Bone formation increased the thickness of trabeculae in all three trabecular orientations (axial, oblique, and transverse, p < 0.05). The volume of bone formed between days 14 to 66 was greater in sclerostin antibody-treated groups (9.0 vs. 5.4%, p = 0.02), and new bone formation due to sclerostin antibody treatment was associated with increased apparent stiffness as determined from finite element models. Our results demonstrate that increased bone formation associated with sclerostin antibody treatment increases plate-like trabecular morphology and improves mechanical performance.
Similar content being viewed by others
References
Genant HK, Delmas PD, Chen P, Jiang Y, Eriksen EF, Dalsky GP, Marcus R, San Martin J (2007) Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int 18:69–76
Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578–588
Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Faseb J 19:1842–1844
Hamersma H, Gardner J, Beighton P (2003) The natural history of sclerosteosis. Clin Genet 63:192–197
Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577–589
Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537–543
Ominsky MS, Niu QT, Li C, Li X, Ke HZ (2014) Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res 29:1424–1430
Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25:948–959
Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C, Jang G (2014) Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol 54:168–178
Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26
McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543
Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289
Delmas PD, Li Z, Cooper C (2004) Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 19:330–337
Hernandez CJ, Keaveny TM (2006) A biomechanical perspective on bone quality. Bone 39:1173–1181
Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25:1468–1486
Liu XS, Sajda P, Saha PK, Wehrli FW, Bevill G, Keaveny TM, Guo XE (2008) Complete volumetric decomposition of individual trabecular plates and rods and its morphological correlations with anisotropic elastic moduli in human trabecular bone. J Bone Miner Res 23:223–235
Zhou B, Liu XS, Wang J, Lu XL, Fields AJ, Guo XE (2014) Dependence of mechanical properties of trabecular bone on plate-rod microstructure determined by individual trabecula segmentation (ITS). J Biomech 47:702–708
Sanchez C, Deberg MA, Piccardi N, Msika P, Reginster JY, Henrotin YE (2005) Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1beta and oncostatin M pre-treated non-sclerotic osteoblasts. Osteoarthr Cartil 13:979–987
Liu XS, Stein EM, Zhou B, Zhang CA, Nickolas TL, Cohen A, Thomas V, McMahon DJ, Cosman F, Nieves J, Shane E, Guo XE (2012) Individual trabecula segmentation (ITS)-based morphological analyses and microfinite element analysis of HR-pQCT images discriminate postmenopausal fragility fractures independent of DXA measurements. J Bone Miner Res 27:263–272
Guo XE, Kim CH (2002) Mechanical consequence of trabecular bone loss and its treatment: a three-dimensional model simulation. Bone 30:404–411
Banse X, Devogelaer JP, Delloye C, Lafosse A, Holmyard D, Grynpas M (2003) Irreversible perforations in vertebral trabeculae? J Bone Miner Res 18:1247–1253
Banse X, Devogelaer JP, Holmyard D, Grynpas M (2005) Vertebral cancellous bone turn-over: microcallus and bridges in backscatter electron microscopy. Micron 36:710–714
Altman AR, Tseng WJ, de Bakker CM, Huh BK, Chandra A, Qin L, Liu XS (2014) A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment. Bone 61:149–157
Altman AR, de Bakker CM, Tseng WJ, Chandra A, Qin L, Liu XS (2015) Enhanced individual trabecular repair and its mechanical implications in parathyroid hormone and alendronate treated rat tibial bone. J Biomech Eng 137:10
Schulte FA, Lambers FM, Kuhn G, Muller R (2011) In vivo micro-computed tomography allows direct three-dimensional quantification of both bone formation and bone resorption parameters using time-lapsed imaging. Bone 48:433–442
Birkhold AI, Razi H, Duda GN, Weinkamer R, Checa S, Willie BM (2014) Mineralizing surface is the main target of mechanical stimulation independent of age: 3D dynamic in vivo morphometry. Bone 66:15–25
de Bakker CM, Altman AR, Tseng WJ, Tribble MB, Li C, Chandra A, Qin L, Liu XS (2015) muCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy. Bone 73:198–207
Lambers FM, Schulte FA, Kuhn G, Webster DJ, Muller R (2011) Mouse tail vertebrae adapt to cyclic mechanical loading by increasing bone formation rate and decreasing bone resorption rate as shown by time-lapsed in vivo imaging of dynamic bone morphometry. Bone 49:1340–1350
de Jong JJ, Willems PC, Arts JJ, Bours SG, Brink PR, van Geel TA, Poeze M, Geusens PP, van Rietbergen B, van den Bergh JP (2014) Assessment of the healing process in distal radius fractures by high resolution peripheral quantitative computed tomography. Bone 64:65–74
Christen P, Ito K, Ellouz R, Boutroy S, Sornay-Rendu E, Chapurlat RD, van Rietbergen B (2014) Bone remodelling in humans is load-driven but not lazy. Nat Commun 5:4855
Ellouz R, Chapurlat R, van Rietbergen B, Christen P, Pialat JB, Boutroy S (2014) Challenges in longitudinal measurements with HR-pQCT: evaluation of a 3D registration method to improve bone microarchitecture and strength measurement reproducibility. Bone 63:147–157
Manhard MK, Nyman JS, Does MD (2016) Advances in imaging approaches to fracture risk evaluation. Transl Res. doi:10.1016/j.trsl.2016.09
Slyfield CR, Tkachenko EV, Wilson DL, Hernandez CJ (2012) Three-dimensional dynamic bone histomorphometry. J Bone Miner Res 27:486–495
Matheny JB, Slyfield CR, Tkachenko EV, Lin I, Ehlert KM, Tomlinson RE, Wilson DL, Hernandez CJ (2013) Anti-resorptive agents reduce the size of resorption cavities: a three-dimensional dynamic bone histomorphometry study. Bone 57:277–283
Slyfield CR Jr, Niemeyer KE, Tkachenko EV, Tomlinson RE, Steyer GG, Patthanacharoenphon CG, Kazakia GJ, Wilson DL, Hernandez CJ (2009) Three-dimensional surface texture visualization of bone tissue through epifluorescence-based serial block face imaging. J Microsc 236:52–59
Cresswell EN, Goff MG, Nguyen TM, Lee WX, Hernandez CJ (2016) Spatial relationships between bone formation and mechanical stress within cancellous bone. J Biomech 49:222–228
Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ (2011) Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26:1012–1021
Doube M, Klosowski MM, Arganda-Carreras I, Cordelieres FP, Dougherty RP, Jackson JS, Schmid B, Hutchinson JR, Shefelbine SJ (2010) BoneJ: free and extensible bone image analysis in ImageJ. Bone 47:1076–1079
Salmon PL, Ohlsson C, Shefelbine SJ, Doube M (2015) Structure model index does not measure rods and plates in trabecular bone. Front Endocrinol 6:1–10
Maquer G, Musy SN, Wandel J, Gross T, Zysset PK (2015) Bone volume fraction and fabric anisotropy are better determinants of trabecular bone stiffness than other morphological variables. J Bone Miner Res 30:1000–1008
Chavassieux P, Portero-Muzy N, Roux JP, Garnero P, Chapurlat R (2015) Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women? J Clin Endocrinol Metab 100:4662–4668
Ross RD, Edwards LH, Acerbo AS, Ominsky MS, Virdi AS, Sena K, Miller LM, Sumner DR (2014) Bone matrix quality after sclerostin antibody treatment. J Bone Miner Res 29:1597–1607
Acknowledgements
Funding and specimens were provided by Amgen Inc. and UCB Pharma. Cornell’s National Science Foundation (NSF) Grant DGE-1,144,153, NSF Graduate Research Fellowship Program (to JBM), NSF Graduate Research Fellowship Program (to AMT), and a Cornell Colman fellowship (to AMT)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Michael Ominsky reports personal fees from Amgen Inc during the conduct of the study; personal fees from Amgen Inc outside the submitted work. Jonathan Matheny and Ashley Torres report non-financial support from Amgen Inc, and UCB Pharma (supplied specimens) during the conduct of the study. Christopher Hernandez reports grants and non-financial support from Amgen Inc and UCB Pharma (supplied specimens) during the conduct of the study. The authors have full control of primary data and agree to journal review of the data if requested.
Ethical Approval
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
Electronic supplementary material
Below is the link to the electronic supplementary material.
223_2017_258_MOESM2_ESM.tif
Correlation Scatterplots for measurements of stiffness derived from high-resolution finite element models and traditional and ITS-based measurements of bone microstructure are shown (TIF 3040 KB)
Rights and permissions
About this article
Cite this article
Matheny, J.B., Torres, A.M., Ominsky, M.S. et al. Romosozumab Treatment Converts Trabecular Rods into Trabecular Plates in Male Cynomolgus Monkeys. Calcif Tissue Int 101, 82–91 (2017). https://doi.org/10.1007/s00223-017-0258-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-017-0258-3